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SUMMARY – Fondaparinux has been shown to be as eff ective as low molecular weight heparin 
in orthopedic surgery, with no cases of heparin induced thrombocytopenia proven until today. Th e 
main goal of this prospective randomized controlled trial was to defi ne whether thromboprophylaxis 
in patients with primary osteoarthritis of the knee undergoing total knee arthroplasty (TKA) infl u-
ences clinical parameters in the same manner in patients receiving fondaparinux as in those receiving 
nadroparin during the fi rst 7 postoperative days. Sixty patients with primary knee osteoarthritis un-
derwent unilateral TKA performed by the same surgeon and were randomized into two groups of 30 
patients receiving either fondaparinux or nadroparin thromboprophylaxis. Patients were compared 
according to the duration of operation, perioperative blood loss, laboratory results and clinical evalu-
ation of the edema during the early postoperative period. No diff erences were found between the 
groups in the mean duration of surgery, perioperative blood loss, and most of laboratory results. Th e 
level of urea was signifi cantly lower in the nadroparin group on the fi rst and second postoperative day. 
No cases of heparin induced thrombocytopenia, deep vein thrombosis or pulmonary embolism were 
noted during the study. Study results showed both fondaparinux and nadroparin to have the same 
infl uence on clinical parameters during the fi rst 7 postoperative days in patients undergoing TKA.
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Introduction
Th e importance of thromboprophylaxis in ortho-
pedic surgery regarding the possible postoperative de-
velopment of thromboembolic complications such as 
deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) is well known. Th e American College of 
Chest Physicians (ACCP) guidelines from 2012 sug-
gest that the baseline risk in orthopedic surgery is 1% 
for PE and 1.8% for DVT1. According to some au-
thors, the rate of DVT can be by 50% higher if no 
thromboprophylaxis is used in orthopedic surgery2. 
Low molecular weight heparin (LMWH) is nowadays 
often used for prevention of thromboembolic compli-
cations in patients undergoing TKA, with the inci-
dence of DVT and PE reduced by 60% when com-
pared to the control group without thromboprophy-
laxis3. Th e known drawbacks in LMWH treatment are 
the possibility of heparin-induced thrombocytopenia 
(HIT) in 0.2% of patients with LMWH therapy and 
excessive bleeding4.
Great attention has been focused lately on devel-
oping an ‘ideal’ medication for prevention and treat-
ment of thromboembolic diseases. Th e ideal drug 
should be as eff ective as the best known drug used to-
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day, safe and simple to use, and widely applicable. Di-
rect inhibitors of factor Xa are being investigated as 
the possible ‘new generation’ of anticoagulants for 
some time5. Fondaparinux is a Xa inhibitor demon-
strated to be as eff ective as LMWH, with no cases of 
HIT proven until today. It inhibits factor Xa via anti-
thrombin III, but is, unlike LMWH, selective for fac-
tor Xa. Th e main goal of this prospective randomized 
controlled trial was to defi ne whether thrombopro-
phylaxis in patients with primary osteoarthritis of the 
knee undergoing TKA infl uences clinical parameters 
in the same manner in patients receiving fondaparinux 
as in those receiving nadroparin calcium during the 
fi rst 7 days following surgery.
Patients and Methods
Our study included 60 patients with primary os-
teoarthritis of the knee that underwent unilateral TKA 
performed by the same surgeon at our Department. 
Th e patients were examined by an anesthesiologist 
working at our Department, 3-4 weeks before the sur-
gery and at that time laboratory results were checked, 
which included complete blood count (CBC), sodium 
and potassium levels, blood glucose level, liver enzymes 
(aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT)), as well as urea and creatinine 
levels. Th e American Society of Anesthesiologists 
(ASA) physical status was assessed at that time6. Th e 
inclusion criteria were primary knee osteoarthritis, age 
between 40 and 80 years, weight between 45 and 110 
kg, and ASA status I and II.
Patients with secondary osteoarthritis of the knee, 
patients awaiting revision TKA, patients with malig-
nancies, autoimmune diseases, coagulation disorders, 
cardiovascular diseases (uncontrolled hypertension, 
unstable angina pectoris, acute myocardial infarction 
and/or cerebrovascular insult up to 6 months prior to 
surgery), gastrointestinal bleeding that had been pres-
ent for up to 6 months prior to surgery, and patients 
taking immunosuppressive or cytostatic drugs or anti-
coagulants were not included in the study.
Upon approval by the Hospital Ethics Committee, 
patients were randomized using the random number 
table into two groups consisting of 30 patients each. 
Th e fi rst group of patients received thromboprophy-
laxis with fondaparinux (Arixtra®, GlaxoSmithKline-
GSK, Brentford, United Kingdom) at a dose of 2.5 mg 
in subcutaneous injections. Th e fi rst dose was adminis-
tered 6 hours after the surgery and the same dose was 
administered each day during the remaining hospital 
stay at 10 a.m.
Th e second group received thromboprophylaxis 
with nadroparin calcium (Fraxiparine®, GlaxoSmith-
Kline-GSK, Brentford, United Kingdom) at a dose of 
0.4 mL in subcutaneous injections. Th e fi rst dose was 
administered 12 hours before the surgery, the second 
dose 8 to 10 hours after the surgery, and then the same 
dose was administered every 24 hours during the hos-
pital stay.
All patients received thromboprophylaxis during 
the fi rst 6 postoperative weeks, which included throm-
boprophylaxis using either fondaparinux or nadropa-
rin calcium throughout the hospital stay, which usually 
ended after the patients achieved at least 90° of fl exion 
and full extension of the operated knee. Upon dis-
charge from the hospital, thromboprophylaxis diff ered 
based on whether they were discharged to a rehabilita-
tion center or home. If the patients were transferred to 
a rehabilitation center, they received thromboprophy-
laxis as suggested by the orthopedic surgeon in the dis-
charge letter. In cases they were discharged home, their 
thromboprophylaxis was converted to oral warfarin at 
a dose adjusted by the attending physician.
Upon admission to the hospital, blood pressure was 
measured, as well as heart frequency and weight. At 
that time, blood sample was obtained to determine 
CBC, activated part ial thromboplastin time (aPTT) 
and prothrombin time (PT). Th is was repeated at 24 
hours, 3 days and 7 days after the surgery. Th e level of 
D-dimers was assessed at 24 hours and 7 days after the 
surgery.
All surgeries were performed with the patients in 
spinal anesthesia. All patients preoperatively received 
antibacterial prophylaxis with fi rst-generation cepha-
losporins or clindamycin, which is in accordance with 
recent guidelines7,8. A thigh tourniquet was infl ated at 
250-300 mm Hg before the beginning of surgery. To-
tal knee arthroplasty was performed in a standard 
fashion in all patients, using the cemented total knee 
endoprosthesis Multigen Plus (Lima Coorporate spa®, 
Udine, Italy). Th e tourniquet was defl ated after the 
original components had been implanted, followed by 
detailed hemostasis and placement of two surgical 
drains intra-articularly before suturing the wound. 
Surgical drains were connected to the autotransfusion 
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Drentech Surgical blood salvage system (REDAX®, 
Poggio Rusco, Italy), which was used during the fi rst 6 
hours postoperatively. Upon removal of the blood sal-
vage system, surgical drains were connected to the 
standard ‘free-fall’ system.
Postoperative care was taken by anesthesiologists 
in the Orthopedic Intensive Care Unit (ICU) for 24 or 
48 hours following the surgery, after which the pa-
tients were transferred back to the orthopedic depart-
ment. Intensive care included fl uid resuscitation and 
continuous use of analgesics. Monitoring of the blood 
pressure, heart and respiratory function and oxygen 
saturation was performed and any complications were 
noted.
Intraoperative and postoperative bleeding was 
measured and local hemorrhage and hematoma was 
noted if present. Intraoperative bleeding implied the 
blood that was aspirated after defl ation of the tourni-
quet and before suturing the wound. It also included 
the blood volume that was present in cheesecloths and 
compresses used during the operation, which was 
measured by weighing them and calculating the diff er-
ence between the used and unused ones.
Total postoperative bleeding consisted of two com-
ponents. Early postoperative bleeding implied the 
blood volume that was collected by the blood salvage 
system during the fi rst 6 hours after the surgery and 
was used for postoperative autotransfusion. On the 
other hand, late postoperative bleeding was the blood 
volume that was drained from the joint in the fi rst 48 
hours after the operation, i.e. until surgical drains were 
removed. Total perioperative bleeding was simply 
counted as intraoperative and postoperative bleeding 
together.
Postoperative rehabilitation was started in the ICU 
with respiration and circulation exercises and was con-
tinued after removal of surgical drains, 48 hours after 
the surgery, and included use of the continuous passive 
motion machine (CPM) and individual exercises. Re-
habilitation was performed in the same way in all pa-
tients and was continued upon their discharge from 
the hospital in another institution with stationary re-
habilitation.
To evaluate postoperative swelling of the operated 
leg, the knee and lower leg circumference was mea-
sured. Th e lower leg circumference was measured at 
two levels, 10 and 15 cm distally to the inferior pole of 
the patella, while the knee circumference was mea-
sured at the level of the middle third of the patella. 
Both measurements were repeated 24, 48 and 72 hours 
after the surgery, as well as 7 days postoperatively.
Statistical analysis was performed using the 
Smirnov-Kolmorgorov testing with ANOVA and 
Kruskal-Wallis test for quantitative variables. Th e c2-
test and Fisher exact test were used on analysis of 
qualitative variables. Th e STATISTICA ver. 9.1 soft-
ware was employed. Th e t-test and Wilcoxon test were 
used to test diff erences, as well as Student’s t-test and 
Mann Whitney test. Th e level of statistical signifi cance 
was set at p<0.05.
Results
Sixty patients were included in our study (24 male 
and 36 female). Sex distribution of study patients was 
comparable in both groups, with 11 male and 19 fe-
male patients receiving fondaparinux versus 13 male 
and 17 female patients receiving nadroparin calcium 
(c2-test, p=0.743). Th e mean age was 66.3 and 66.5 
years in the fondaparinux group and nadroparin calci-
um group, respectively (Student’s t-test, p=0.749). 
Th ere was no statistically signifi cant between-group 
diff erence in BMI (Student’s t-test, p=0.390) and 
weight (Student’s t-test, p=0.270).
Th e mean duration of surgery was similar in both 
groups with a mean of 103 minutes in the fondaparinux 
group and 113.3 minutes in the nadroparin calcium 
group (Student’s t-test, p=0.239). Th e mean volume of 
intraoperative bleeding, postoperatively autotrans-
fused blood, late postoperative bleeding and perioper-
ative bleeding, as well as the mean volume of trans-
fused blood are shown in Figure 1.
Blood test results were similar in both groups when 
comparing red blood cell (RBC) count, hemoglobin 
and hematocrit level (Table 1). Th e dynamics of hemo-
globin level diff ered between the groups, with a con-
tinuous decrease in the fondaparinux group and an 
increase in the nadroparin calcium group at 72 h post-
operatively. Platelet level was similar in both groups, 
decreasing during the fi rst 48 h postoperatively, fol-
lowed by a continuous increase thereafter. No cases of 
HIT were recorded in the study.
Between-group diff erences in the AST and ALT 
levels did not reach statistical signifi cance. Neverthe-
less, diff erent dynamics was observed, with an increase 
during the fi rst 48 h postoperatively in the nadroparin 
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calcium group, followed by a decrease of AST and ALT 
levels versus continuous decrease in AST and ALT lev-
els in the fondaparinux group throughout the hospital 
stay. A statistically signifi cant between-group diff er-
ence was found in the level of urea, which was signifi -
cantly lower in the nadroparin calcium group on the 
fi rst and second postoperative day (p=0.028 and 
p=0.048, respectively), as shown in Table 2. Th e levels 
of D-dimers were higher in the nadroparin calcium 
group at both 24 h and 7 days after the surgery, but it 
was not statistically signifi cant (Table 3). Th e clinical 
signs of the knee and lower leg edema were similar in 
both groups with no statistically signifi cant diff erences.
Th e postoperative course was uneventful in all 
study patients, with no cases of DVT or PE in the 
early postoperative period.
Discussion
Many studies have shown the benefi cial eff ects of 
fondaparinux in the prevention of thromboembolic 
diseases in orthopedic surgery5,9-13. Our study results 
were in favor of these data, showing both fondaparinux 
and nadroparin calcium to be safe and effi  cient during 
the fi rst 7 days after TKA.
Nevertheless, caution is advised by the ACCP 
guidelines in patients weighing less than 45 kg and the 
elderly when applying fondaparinux because of the in-
creased bleeding risk. Demographic data showed that 
there were no signifi cant diff erences among study pa-
tients at the beginning of the study; the mean body 
weight was 85.7 kg, with lowest weight of 65 kg in 
both groups.
Th e duration of the surgery was expectedly similar in 
both groups because of the same type of osteoarthritis 
(primary), similar age, BMI, and the same orthopedic 
surgeon performing all the operations with the same 
endoprosthesis model. Th e tourniquet was used in the 
same fashion in all patients, which is one of the main 
factors infl uencing the duration of TKA and possible 
intraoperative and postoperative complications14.
We used nadroparin calcium in the control group 
because LMWH is usually the fi rst choice for periop-
erative thromboprophylaxis in orthopedic surgery. In 
this way, fondaparinux was compared to the standard 
of care in our country and region. According to ACCP, 
the application of LMWH in orthopedic surgery is 
advised at least 12 h before (preoperative application) 
or 12 h after the surgery (postoperative application). In 
our department, we have good experience with preop-
erative application of LMWH and that was the reason 
why we decided to use this type of thromboprophy-
laxis. Th is could also explain the larger intraoperative 
bleeding in patients receiving LMWH due to the an-
ticoagulant eff ect that is present during the operation.
Following the surgery, the blood salvage system col-
lects the blood for the fi rst 6 h after the surgery and 
then autotransfusion is initiated. Only at that time, 
when the blood salvage system is disconnected, the fi rst 
dose of fondaparinux was administered, which could 
Fig. 1. Perioperative blood loss: chart showing the mean volume of intraoperative bleeding, postoperative 
autotransfused blood, postoperative bleeding, total perioperative bleeding and postoperative allotransfusion 
in each group, and the mean in all patients.
TRANSFUSION AFTER SURGERY (ml) (p = 0.020)
TOTAL PERIOPERATIVE BLEEDING (ml) (p = 0.72)
POSTOP BLEEDING (ml) (p = 0.62)
0 200 400 600 800 1000 1200 1400 1600 1800
POSTOP AUTOTRANSFUSION  (ml) (p = 0.65)
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explain the lower volume of postoperatively autotrans-
fused blood in the fondaparinux group. In addition, in 
patients on fondaparinux, there is no risk of the possi-
ble development of spinal hematoma. We hypothesize 
that the late postoperative bleeding was greater in this 
group for the same reason. Th e statistically signifi cant 
diff erence was found only in the volume of allotrans-
fused blood, which was on average greater in the nad-
roparin calcium group. Th is could lead to a conclusion 
that patients on fondaparinux have less need for post-
operative allotransfusion due to the less intraoperative 
and early postoperative bleeding.
A recent study by Hosaka et al.10 confi rmed the 
opinions from previous studies that excessive bleeding 
can be expected in patients undergoing surgery and 
receiving fondaparinux5,12,15-17. In their study, Hosaka 
et al. assessed the safety of fondaparinux versus enoxa-
parin after TKA in Japanese patients and concluded 
that thigh swelling and subcutaneous hematomas were 
greater in the fondaparinux group. Th ey hypothesize 
that it is due to the same dose (2.5 mg daily) which all 
patients receive regardless of their body mass and the 
fact that Japanese patients are smaller than Western 
populations10. In our study, we found no diff erences in 
the knee or lower leg swelling between the groups, 
suggesting that no excessive bleeding was found in the 
fondaparinux group, which could partly be explained 
by the fact that most of our patients undergoing TKA 
were overweight with the mean BMI of 29.4 (range, 
21.6-42) kg/m2.
In addition, we recorded the levels of hemoglobin 
and hematocrit preoperatively and during the fi rst 3 
days after the surgery and found no statistically sig-
nifi cant diff erence between the groups, which also 
confi rmed that there was no excessive bleeding in the 
fondaparinux group. Diff erent dynamics of hemoglo-
bin levels, with an earlier increase in the nadroparin 
calcium group could be explained again by earlier ini-
tiation of thromboprophylaxis in this group. Th e plate-
let level decreased in both groups during the fi rst 48 h 
of the surgery, which could be explained by fl uid resus-
citation the patients received in the ICU and subse-
quent hemodilution.
Some anticoagulants have been withdrawn from 
the market because of their side eff ects on the liver 
function18. Our results showed an increase in AST and 
ALT levels immediately after the surgery in the pa-
tients receiving nadroparin calcium, while in the pa-
tients receiving fondaparinux the levels of AST and 
ALT decreased throughout their hospital stay. Al-
though it is known that LMWH can lead to an in-
crease of ALT level, it is hypothesized that this in-
crease does not pose a problem for liver function, but is 
simply a reaction to direct stimulation of hepatocytes, 
immunoreaction, or a transient increase of LMWH 
half-life19. None of our patients developed any symp-
toms regarding liver function and no further examina-
tion was needed regarding this issue.
Th e signifi cantly lower levels of urea in the nad-
roparin calcium group on the fi rst and second postop-
erative day were noted, although there were no diff er-
ences between the groups preoperatively. Although 
low, the values of urea were within the reference values 
throughout the hospital stay, with the lowest urea val-
ue of 3.47 mmol/L, and there were no between-group 
diff erences in creatinine levels. We believe that the 
lower levels of urea may have been caused by iatro-
genic hyperhydration during the early postoperative 
period in the ICU.
Increased levels of D-dimers can be a sign of serious 
complications such as DVT or PE, but can also be ex-
pected to increase after surgery because of the local tis-
sue trauma. Although in other studies blood vessel echo 
was performed to check for the possible intraluminal 
signs of thrombosis, the treatment policy of our depart-
ment is to perform this type of imaging only in symp-

















24 h postop. 20 26.15 0.246 60.38 52.29 0.497 9.24 13.35 0.075
7 days postop. 73.85 78.15 0.666 97.91 74.93 0.238 4.1 5.62 0.013
Values are shown as mean except where stated diff erently; postop. = postoperatively
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tomatic patients, and none of our patients developed 
symptoms suggesting development of DVT or PE5,10.
Th e main limitation of this study was a relatively 
small number of patients. However, the study was per-
formed in a single center, by a single surgeon, and only 
in patients undergoing elective TKA, which limited 
the number of diff erent factors infl uencing the results 
of this study. In addition, power analysis was per-
formed to determine the sample size needed for the 
study with acceptable power level (80%).
No cases of DVT or PE were recorded in our study, 
and there was no case of excessive perioperative bleed-
ing or the need for revision of the wound. We there-
fore believe that both fondaparinux and nadroparin 
calcium are safe and eff ective in thromboprophylaxis 
during the fi rst 7 days after surgery in patients under-
going TKA, with the same infl uence on clinical pa-
rameters in both groups. Additional studies in a great-
er number of patients should clarify the issue whether 
there is less need for postoperative transfusion in pa-
tients receiving fondaparinux.
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Sažetak
UTJECAJ TROMBOPROFILAKSE FONDAPARINUKSOM U USPOREDBI S NADROPARIN KALCIJEM 
NA KLINIČKE PARAMETRE NAKON UGRADNJE POTPUNE ENDOPROTEZE KOLJENA
Z. Mihaljević, D. Dimnjaković, B. Tripković, M. Buljan, A. Aljinović, D. Delimar i G. Bićanić
Fondaparinuks se pokazao jednako učinkovitim u ortopedskim operacijama kao i heparin niske molekularne težine, bez 
slučajeva heparinom izazvane trombocitopenije do danas. Glavni cilj ovoga prospektivnog randomiziranog istraživanja bio je 
pokazati utječe li tromboprofi laksa fondaparinuksom na bolesnike s primarnom gonartrozom koji su podvrgnuti operacij-
skom zahvatu ugradnje totalne endoproteze koljena na jednaki način kao i nadroparin tijekom prvih 7 dana nakon operacije. 
Ukupno 60 bolesnika kod kojih je jednostranu ugradnju totalne endoproteze koljena izveo jedan te isti operater randomizi-
rani su u dvije skupine po 30 bolesnika te je jedna skupina dobivala tromboprofi laksu fondaparinuksom, a druga nadropari-
nom. Bolesnici su uspoređivani prema trajanju operacije, perioperacijskom gubitku krvi, laboratorijskim nalazima te kliničkoj 
evaluaciji edema tijekom ranog poslijeoperacijskog razdoblja. Nisu nađene razlike u trajanju operacijskog zahvata, periope-
racijskom gubitku krvi niti prema većini laboratorijskih nalaza. Razina ureje je bila značajno niža u skupini s nadroparinom 
tijekom prva dva poslijeoperacijska dana. Nije zabilježen niti jedan slučaj heparinom izazvane trombocitopenije, duboke 
venske tromboze ili plućne embolije tijekom ovog istraživanja. Naši rezultati pokazali su da fondaparinuks i nadroparin na 
isti način utječu na kliničke parametre tijekom prvih 7 poslijeoperacijskih dana od ugradnje totalne endoproteze koljena.
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